This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.
Top Stock Reports for Salesforce, Booking Holdings & VMware
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including salesforce (CRM), Booking Holdings (BKNG) and VMware (VMW).
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
by Zacks Equity Research
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.
Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion
by Zacks Equity Research
The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron (REGN) disagree with a jury verdict in favor of Amgen upholding the validity of two patents related to Repatha.
Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and a revenue beat in Q4.
BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline
by Zacks Equity Research
BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.
Ascendis Pharma Files IND for Hypoparathyroidism Candidate
by Zacks Equity Research
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%
by Zacks Equity Research
Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.
ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in Q4 and beats revenue estimates.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
by Zacks Equity Research
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
by Zacks Equity Research
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea
by Zacks Equity Research
Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.
The Zacks Analyst Blog Highlights: Pepsico, Disney, Sanofi, Diageo and HCA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pepsico, Disney, Sanofi, Diageo and HCA
Top Ranked Income Stocks to Buy for February 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, February 6th:
Can Sanofi (SNY) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Sanofi (SNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Top Research Reports for Pepsico, Walt Disney & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pepsico (PEP), Walt Disney Company (DIS) and Sanofi (SNY).
Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.
Merck's Pneumococcal Vaccine Gets Breakthrough Therapy Status
by Zacks Equity Research
Merck's (MRK) investigational pneumococcal vaccine V114 gets FDA's Breakthrough Therapy designation for prevention of invasive pneumococcal disease.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV
by Zacks Equity Research
J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Top Ranked Income Stocks to Buy for January 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, January 25th: